> Details
Carlucci, Philip M;
Li, Jessica;
Fava, Andrea;
Deonaraine, Kristina K;
Wofsy, David;
James, Judith A;
Putterman, Chaim;
Diamond, Betty;
Davidson, Anne;
Fine, Derek M;
Monroy-Trujillo, Jose;
Atta, Mohamed G;
DeJager, Wade;
Guthridge, Joel M;
Haag, Kristin;
Rao, Deepak A;
Brenner, Michael B;
Lederer, James A;
Apruzzese, William;
Belmont, H Michael;
Izmirly, Peter M;
Zaminski, Devyn;
Wu, Ming;
Connery, Sean;
[...]
High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership
Sharing
Reference
management
Direct link
Bookmarks
Remove from
bookmarks
Share this by email
Share this on Twitter
Share this on Facebook
Share this on Whatsapp
- Media type: E-Article
- Title: High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership
- Contributor: Carlucci, Philip M; Li, Jessica; Fava, Andrea; Deonaraine, Kristina K; Wofsy, David; James, Judith A; Putterman, Chaim; Diamond, Betty; Davidson, Anne; Fine, Derek M; Monroy-Trujillo, Jose; Atta, Mohamed G; DeJager, Wade; Guthridge, Joel M; Haag, Kristin; Rao, Deepak A; Brenner, Michael B; Lederer, James A; Apruzzese, William; Belmont, H Michael; Izmirly, Peter M; Zaminski, Devyn; Wu, Ming; Connery, Sean; [...]
- imprint: Oxford University Press (OUP), 2022
- Published in: Rheumatology
- Language: English
- DOI: 10.1093/rheumatology/keac067
- ISSN: 1462-0324; 1462-0332
- Keywords: Pharmacology (medical) ; Rheumatology
- Origination:
- Footnote:
- Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Delayed detection of LN associates with worse outcomes. There are conflicting recommendations regarding a threshold level of proteinuria at which biopsy will likely yield actionable management. This study addressed the association of urine protein:creatinine ratios (UPCR) with clinical characteristics and investigated the incidence of proliferative and membranous histology in patients with a UPCR between 0.5 and 1.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A total of 275 SLE patients (113 first biopsy, 162 repeat) were enrolled in the multicentre multi-ethnic/racial Accelerating Medicines Partnership across 15 US sites at the time of a clinically indicated renal biopsy. Patients were followed for 1 year.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>At biopsy, 54 patients had UPCR &lt;1 and 221 had UPCR ≥1. Independent of UPCR or biopsy number, a majority (92%) of patients had class III, IV, V or mixed histology. Moreover, patients with UPCR &lt;1 and class III, IV, V, or mixed had a median activity index of 4.5 and chronicity index of 3, yet 39% of these patients had an inactive sediment. Neither anti-dsDNA nor low complement distinguished class I or II from III, IV, V or mixed in patients with UPCR &lt;1. Of 29 patients with baseline UPCR &lt;1 and class III, IV, V or mixed, 23 (79%) had a UPCR &lt;0.5 at 1 year.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In this prospective study, three-quarters of patients with UPCR &lt;1 had histology showing class III, IV, V or mixed with accompanying activity and chronicity despite an inactive sediment or normal serologies. These data support renal biopsy at thresholds lower than a UPCR of 1.</jats:p></jats:sec>
- Access State: Open Access